secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cellectar Biosciences, Inc. (CLRB)
CIK:        0001279704
Form:       8-K
Filed at:   2021-11-02T23:59:59+00:00
Accession:  0001104659-21-132991
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cellectar receives Nasdaq non-compliance notice; appoints Laurence Reilly as interim CMO
--------------------------------------------------------------------------------

- Received Nasdaq deficiency notice for bid price below $1 for 30 consecutive business days; has 180 days until May 2, 2022 to cure.
- Appointed Laurence Reilly as interim CMO effective Nov 2; John Friend departs for personal reasons after transition.
- Company asserts sufficient cash into 2H 2023; focused on iopofosine I-131 registrational trial in WM and other programs.
- Dr. Reilly previously consulted for Cellectar; experience at Pfizer and Avillion; will oversee clinical development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1279704/000110465921132991/0001104659-21-132991-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1279704/000110465921132991/tm2131707d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-132991

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer